Is the clinical and regulatory update Mirati Therapeutics (MRTX) provided Monday for its lead lung cancer cancer immunotherapy drug really positive? That’s what the biotech chose to say in the headline of its press release. The details, disclosed for the first time, are far more concerning.
Mirati is one of many biotechs developing new immunotherapy drugs that are meant to combine with existing checkpoint inhibitors like Merck’s Keytruda or Bristol-Myers Squibb’s Opdivo. The idea is that combinations of immunotherapies will provide greater benefit to a larger group of patients than checkpoints can achieve on their own.
About the Author Reprints
